Credit Suisse’s Monte Rosa Therapeutics GLUE Stock Holding History

Credit Suisse’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$110K	Sell	15,600 -4,400	-22%	-$26.1K	﹤0.01%	2929
2023 Q4	$113K	Sell	20,000 -45,353	-69%	-$178K	﹤0.01%	3023
2023 Q3	$313K	Buy	65,353 +11,624	+22%	+$74.8K	﹤0.01%	2919
2023 Q2	$368K	Buy	53,729 +20,090	+60%	+$130K	﹤0.01%	2930
2023 Q1	$262K	Buy	33,639 +5,766	+21%	+$40.1K	﹤0.01%	3042
2022 Q4	$212K	Buy	27,873 +5,660	+25%	+$47.1K	﹤0.01%	3162
2022 Q3	$181K	Buy	22,213 +12,136	+120%	+$111K	﹤0.01%	3282
2022 Q2	$98K	Buy	+10,077	New	+$101K	﹤0.01%	3532

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Credit Suisse's GLUE Position: Q1 2024 in Review

Credit Suisse reduced its Monte Rosa Therapeutics (GLUE) stake by 22% in Q1 2024, selling an estimated $26.1K and leaving 15,600 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #2929.

Credit Suisse first reported a position in GLUE in Q2 2022 and has held it in 8 quarters since. The position peaked at $368K in Q2 2023. 68 funds tracked by Wall St. Rank hold GLUE as of Q1 2024.

Credit Suisse held 15,600 shares of Monte Rosa Therapeutics worth $110K as of Q1 2024.
Credit Suisse sold 4,400 Monte Rosa Therapeutics shares in Q1 2024, an estimated $26.1K.
Monte Rosa Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2929 holding.
Credit Suisse first reported a position in Monte Rosa Therapeutics in Q2 2022 and has held it in 8 quarters since.
Credit Suisse's Monte Rosa Therapeutics position peaked at $368K in Q2 2023.
68 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.